Company intelligence / Profile preview

Catalyia

Ownership: Private
Development stage: Commercial

Overview

Catalya is a Belgian biotech company developing a proprietary synthetic polymer platform with two main applications—improving drug delivery as an excipient for both small molecules and biopharmaceuticals, and enabling scalable adherent cell growth in 2D/3D cultures. The company’s technologies are designed to enhance oral/nasal absorption of therapeutics for CNS/systemic use and address challenges in stem cell culture scale-up. No clinical results or pipeline drugs have been disclosed publicly as of June 2025.

Therapeutic areas: ImmunologyNeurology
Modalities: Small moleculeBiologicSynthetic polymer
Industry: Non-Drug Biotech

Partnerships

Not specified; no major pharmaceutical or biotech partnerships publicly announced.

Beyond the preview

Go deeper on Catalyia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Catalyia.

Explore the full profile